Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.

[1]  I. Durieu,et al.  FEIBA in the treatment of acquired haemophilia A: Results from the prospective multicentre French ‘FEIBA dans l'hémophilie A acquise’ (FEIBHAC) registry , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  D. Long,et al.  Interventions for treating acute bleeding episodes in people with acquired hemophilia A. , 2014, The Cochrane database of systematic reviews.

[3]  P. Cortesi,et al.  Health‐related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti‐inhibitor complex concentrate: results from the Pro‐FEIBA study , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  J. Stockman.  Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors , 2013 .

[5]  S. Kang,et al.  Acquired hemophilia successfully treated with activated prothrombin complex concentrate and immunosuppressant combination: a case report. , 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[6]  F. Pellegrini,et al.  Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). , 2012, Blood.

[7]  F. Pellegrini,et al.  Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. , 2012, Blood.

[8]  P. Holme,et al.  Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A – a two‐centre experience , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  J. Esser,et al.  Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) , 2012, Journal of thrombosis and haemostasis : JTH.

[10]  C. Kessler,et al.  Consensus recommendations for the diagnosis and treatment of acquired hemophilia A , 2010, BMC Research Notes.

[11]  P. Smejkal,et al.  FEIBA® in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  C. Kessler,et al.  International recommendations on the diagnosis and treatment of patients with acquired hemophilia A , 2009, Haematologica.

[13]  S. Seremetis,et al.  Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  R. Liesner,et al.  The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation , 2006, British journal of haematology.

[15]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[16]  S. Sallah.  Treatment of acquired haemophilia with factor eight inhibitor bypassing activity , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  H. Ehrlich,et al.  Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  M. Griesshammer,et al.  Acquired haemophilia: experiences with a standardized approach , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  C. Kessler,et al.  Treatment of acquired hemophilia. , 1994, Seminars in hematology.

[20]  C. Kessler,et al.  An introduction to factor VIII inhibitors: the detection and quantitation. , 1991, The American journal of medicine.